PriceTargets.com logo

Latigo Biotherapeutics - LTGO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $52.25
  • Forecasted Upside: 126.78%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$23.04 As of 09/4/2026 05:00 PM ET
▲ +0.56 (2.49%)

This chart shows the closing price for LTGO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Latigo Biotherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LTGO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LTGO

Analyst Price Target is $52.25
▲ +126.78% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Latigo Biotherapeutics in the last 3 months. The average price target is $52.25, with a high forecast of $73.00 and a low forecast of $36.00. The average price target represents a 126.78% upside from the last price of $23.04.

This chart shows the closing price for LTGO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Latigo Biotherapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/14/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/6/2026
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2026

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/1/2026Jefferies Financial GroupInitiated CoverageBuy$50.00
9/1/2026Leerink PartnersInitiated CoverageOutperform$36.00
9/1/2026GuggenheimInitiated CoverageBuy$50.00
9/1/2026The Goldman Sachs GroupInitiated CoverageBuy$73.00
9/1/2026Leerink PartnersInitiated CoverageOutperform$36.00
9/1/2026Jefferies Financial GroupInitiated CoverageBuy$50.00
9/1/2026GuggenheimInitiated CoverageBuy$50.00
9/1/2026The Goldman Sachs GroupInitiated CoverageBuy$73.00
(Data available from 9/5/2021 forward)

News Sentiment Rating

0.05 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/7/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/9/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/8/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/6/2026
  • 2 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
9/5/2026

Current Sentiment

  • 2 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Latigo Biotherapeutics logo
Latigo Biotherapeutics Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its lead product candidate includes LTG-001. Latigo Biotherapeutics Inc. is based in THOUSAND OAKS, Calif.
Read More

Today's Range

Now: $23.04
Low: $22.02
High: $23.57

50 Day Range

MA: N/A

52 Week Range

Now: $23.04
Low: $17.22
High: $25.93

Volume

226,438 shs

Average Volume

380,648 shs

Market Capitalization

$1.46 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Latigo Biotherapeutics?

The following Wall Street analysts have issued stock ratings on Latigo Biotherapeutics in the last year: Guggenheim, Jefferies Financial Group Inc., Leerink Partners, The Goldman Sachs Group, Inc., and Wall Street Zen.
View the latest analyst ratings for LTGO.

What is the current price target for Latigo Biotherapeutics?

0 Wall Street analysts have set twelve-month price targets for Latigo Biotherapeutics in the last year. Their average twelve-month price target is $52.25, suggesting a possible upside of 126.8%. The Goldman Sachs Group, Inc. has the highest price target set, predicting LTGO will reach $73.00 in the next twelve months. Leerink Partners has the lowest price target set, forecasting a price of $36.00 for Latigo Biotherapeutics in the next year.
View the latest price targets for LTGO.

What is the current consensus analyst rating for Latigo Biotherapeutics?

Latigo Biotherapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LTGO will outperform the market and that investors should add to their positions of Latigo Biotherapeutics.
View the latest ratings for LTGO.

How do I contact Latigo Biotherapeutics' investor relations team?

The company's listed phone number is 805-716-2927 and its investor relations email address is [email protected]. The official website for Latigo Biotherapeutics is latigobio.com. Learn More about contacing Latigo Biotherapeutics investor relations.